



BioPharma Research
Council

June 13, 2013

For Immediate Release

Contact: Dolly Koltchev, Ph.D.

Program Director

dkoltchev@biopharmaresearchcouncil.org

732-933-9473 x 807

BRC Therapeutics Forum: Virology (Vaccines)
September 17, 2013, 5:30-8:00 PM at Princeton Marriott

(Princeton, NJ) The BioPharma Research Council (BRC) presents the BRC Therapeutics Forum on Virology (Vaccines) on September 17 at the Marriott Hotel in Princeton, NJ. The program will be relevant for academic and industry pharmaceutical researchers and drug developers, as well as medical professionals.

This conference will address two serious diseases that pose a range of threats and treatment obstacles, the Herpes simplex virus (genital herpes) and Zoster (more commonly known as Shingles). Along with a number of discussions about the progress in the treatment for these diseases, the conference will have two papers presented that evaluate different subunit antigen vaccines; one for herpes simplex and the other for zoster.

Thomas Heineman, Ph.D., Director of Global Clinical Development in Vaccines at GlaxoSmithKline Biologicals, will present a paper concerning Herpes Zoster, entitled "New Directions in Herpes Zoster Vaccine Development". Harvey M. Freidman, MD, Professor of Medicine/ Infectious Disease and the Director of the Botswana-UPenn Partnership at the University of Pennsylvania, will present a paper concerning Genital Herpes, entitled "An HSV-2 subunit glycoprotein vaccine that protects by preventing immune evasion".

"The papers being presented will demonstrate important developments in the treatment of serious conditions and a great deal of potential for long term solutions in virology" says Dolly Koltchev Ph.D., the Program Director. "By exposing findings from such accomplished academics to pharmaceutical professionals seeking there is immense potential to improve the treatment of these serious diseases."

For more information and registration, please visit www.biopharmaresearchcouncil.org or call Joanne Gere, Executive Director, at 732-403-3137.

---###---